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ABSTRACT
Risperidone and olanzapine in treatment of psychiatric patients can provoke a plethora of tardive dyskinesias which pose problems for
them. This clinical problem requires the urgent attention of mental health professionals. Hence a comprehensive research of Medline
and related literature was undertaken from 1996 till August 2004. The published twenty two cases of risperidone (N=12) or olanzapine
(N=10) induced tardive dyskinesia were critically reviewed and an attempt is being made to clarify the various issues associated with
them. In these reports majority of patients were in younger age group, females and the interval until onset of tardive dyskinesia after
initiation of risperidone or olanzapine was within one year. In eight reported cases of risperidone induced and three cases of olanzapine
induced tardive dyskinesia, TD disappears either by stopping the drug or switching to other atypical antipsychotic drug. In seven
cases of risperidone induced and three cases of olanzapine induced tardive dyskinesia, there was previous exposure to conventional
antipsychotic drugs. It is concluded that induction of tardive dyskinesia by these medications is insufficiently documented in these
reports but in some cases evidence is suggestive of the role of these drugs in development of tardive dyskinesia. There is no generally
accepted treatment for tardive dyskinesia, thus long term studies with risperidone and olanzapine are needed in future to ascertain their
tardive dyskinesia liability. Mental health professionals must remain vigilant about onset of tardive dyskinesia with these medications.
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Introduction
The first published report on tardive dyskinesia is generally
credited to Schonecker in 1957. Since then tardive
dyskinesia (TD) remains an important clinical problem.
These days atypical antipsychotics are widely used in day
to day clinical practice. These are reported to have superior
extrapyramidal side effect profile to that of conventional
antipsychotics (Glazer, 2000). Furthermore it is claimed that
the prevalence of tardive dyskinesia has dropped markedly
with a switch from neuroleptics to atypical antipsychotics
(Jeste, 2004; Friedman, 2004).
During the last decade a number of novel antipsychotics
drugs in the market have been launched. These molecules
have come with substantial number of studies supporting
their use, reduced liability for inducing tardive dyskinesia
and antidyskinetic properties. This has fascinated the young
clinicians to try them in large number of patients. The
appearance of atypical antipsychotics has opened new
paths. Risperidone and olanzapine appear to be effective
in psychotic patients, but several authors report cases of
tardive dyskinesia during maintenance therapy with these
drugs. They are doubtlessly promising, but the notion of
risk-benefit aspects of these medications cannot be ignored
(Lloraca, 2002).
These medications have not been used long enough or
adequately studied for their effects on tardive dyskinesia.
Rising number of case reporting of risperidone or olanzapine
induced tardive dyskinesia is a matter of concern. It has
been revealed that with these novel antipsychotics certain
amount of complacency exists (Simpson,2000). As tardive
dyskinesia is relatively under recognized in the clinical setting
(Hansen et al, 1992), possibility of lesser reporting of such
cases in the literature cannot be ruled out.
Effects of olanzapine and risperidone on tardive dyskinesia
are less clear. These published cases raise interest in this
important clinical problem and this review was conducted
to clarify the role played by risperidone or olanzapine in
development of tardive dyskinesia.
Material and Methods
An extensive MEDLINE search and review of the
literature from January 1996 till August 2004 was undertaken
to collect the data of reported cases of tardive dyskinesia
by risperidone or olanzapine. The search terms used were
risperidone, olanzapine and tardive dyskinesia. Indian
literature was also searched manually and total twenty two
(N=22) reported cases were critically analyzed. Various
parameters selected from these cases were age and sex
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distribution of patients, clinical diagnosis, dose of the drug,
interval until onset, previous exposure to the other drugs as
well as co-medication and outcome of tardive dyskinesia in
such patients. Twelve cases of risperidone induced tardive
dyskinesia were reported (N=12) and ten cases were
associated with olanzapine (N=10).
Critical review
Reported cases of risperidone induced tardive dyskinesia
are presented in Table No. 1 and 2. Similarly the case reports
of olanzapine and tardive dyskinesia are depicted in Table
No. 3. These cases revealed that the patients were mostly
in the younger age group.
The age of patients with reported cases was in the range
of 16-56 years (Median age 28 years). Similar figure with
olanzapine reported cases was in range of 21-71 years
(median age 30 years). Females constituted the majority of
cases in these reports. Regarding diagnosis schizophrenia
represented a large majority of cases reported for both
risperidone and Olanzapine (N=17). Interval until onset was
within one year in majority of these cases. Median interval
in risperidone induced cases was four months and in
olanzapine reported cases, it was seven months. In some
cases these patients were given risperidone or olanzapine
as monotherapy and no typical antipsychotics were used.
In seven cases of risperidone induced and three cases of
olanzapine induced tardive dyskinesia, there was previous
exposure to conventional antipsychotic drugs.
The dose of risperidone used was in the range of 2-12 mg/
day while olanzapine dose was 10-30mg/day in these
reports. In risperidone induced tardive dyskinesia, eight
patients reported disappearance of tardive dyskinesia after
either stopping risperidone or switching to other atypical
antipsychotic drug or by dose reduction In three cases of
risperidone induced tardive dyskinesia, olanzapine is used.
In two cases of olanzapine induced tardive dyskinesia,
quetiapine has been used. Even as monotherapy agents, in
three cases of risperidone and five cases of olanzapine used
published reports, patients have developed tardive
dyskinesia. In these patients there was no previous exposure
to conventional antipsychotics. In such cases, evidence is
narrated which is suggestive of the role of these drugs in
development of tardive dyskinesia. In some cases precise
information about the required reviewed parameters  was
lacking and thus caused complications in interpretation of
Table 1
RISPERIDONE AND TARDIVE DYSKINESIA-I
Sl. Author Diagnosis Drug Dose Interval Medication Co- Outcome
No. (Age, Gender) (mg/ until until onset medication
day) Onset
1. Woerner Undifferentiated Risperi- 6 mg 1 year Trifluoperazine None TD persisting
et al schizophrenia done on 6mg/day
(1996) (31 yrs., Male)
2. Buzan Bipolar  mood Risperi- 6 mg 4  weeks Lithium + other Lithium Resolution
(1996) disorder done neuroleptics, carbamazepine, after
(46 yrs., Female) carbamazepine, levothyroxine, discontinuation
valproic acid & Vit.E
levothyroxine
3. Sue Hong Schizophrenia Risperi- 1 mg 5 None Trihexyphenidyl Minimized with
et al (1999) (21 yrs., Female) done months 2.5 mg/day change to sul-
piride 100mg
4. Jaffe and Schizophrenia Risperi-  6 mg 10 year Chlorpromazine None TD improved
Simpson (43 yrs., Male) done 1000 mg for with change to
(1999) 14 years olanzapine
15 mg
5. Vasudevan Paranoid Risperi- 8 mg 18 None Trihexyphenidyl Olanzapine
et al Schizophrenia done months 2mg/day 7.5 mg started
(2002) (56yr., Female) but TD persists.
6. Daniel et al Undifferentiated Risperi- 2-3mg 4 Thioridazine, Fluoxetine Risperidone &
(1996) Schizophrenia done months Trifluoperazine, fluoxetine
(18 yr., Male) Fluphenazine discontinued;
TD much
attenuated
7. Silberbalker Schizophrenia, Risperi- *** 1 year Classic None ****
(1998) 28 yrs,Male done neuroleptics
Note: ***=information not available
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the data. Thus several limitations were taken into
consideration while analyzing these reported cases.
Discussion
Tardive dyskinesia remains a major clinical problem despite
the introduction of atypical antipsychotics a decade ago. It
is claimed that patients with tardive dyskinesia who are
taking conventional antipsychotics are candidates to be
switched to an atypical antipsychotic (Simpson, 2000). But
number of reported cases of tardive dyskinesia with
risperidone or olanzapine has doubled over last 3-4 years.
Tardive dyskinesia with atypical antipsychotics has been
the subject of increasing attention in the third millennium.
This could be attributed to increased prescription of these
drugs and for a longer period these days.
Several risk factors for tardive dyskinesia have been
identified, such as advanced age and duration of illness
(Kane et al, 1992). But these case reports findings have
shown that tardive dyskinesia can occur at a relatively
younger age with risperidone or olanzapine.
Among other risk factor regarding sex, females experience
a higher frequency of tardive dyskinesia. This observation
is also revealed in these reported cases. The reason could
be the influence of oestrogen on the occurrence of tardive
dyskinesia. There may be additive effects of oestrogen and
atypical antipsychotics on dopamine blockade. Even in
postmenopausal women oestrogen decline may precipitate
tardive dyskinesia by relieving this dopamine blockade. Thus
presence of oestrogen in the young and lack of it in old age
may be associated with tardive dyskinesia in females.
By critical review of twenty two cases of tardive dyskinesia
associated with olanzapine or risperidone it can be
commented that some patients may develop tardive
dyskinesia while taking risperidone or olanzapine. The
induction of tardive dyskinesia with risperidone or olanzapine
raises the critical issue of the effects of other atypical
antipsychotics which are used in clinical practice. Some of
these have been recently introduced in the market. Tardive
dyskinesia can be induced by clozapine (Kumet and
Freeman, 2002), quetiapine (Ghelber and Belmaker, 1999).
No such case report till recent have been reported with
ziprasidone or aripiprazole. Animal models have also
demonstrated that atypical antipsychotic can cause
involuntary movements (Tamming et al, 1994).
Another important issue pertains to the fact that tardive
dyskinesia is induced by one atypical antipsychotic drug
and switching to other atypical antipsychotic tardive
dyskinesia disappears (case number 3, 4, 10-13). In some
Table 2
RISPERIDONE AND TARDIVE DYSKINESIA -II
Sl. Author Diagnosis Drug Dose Interval Medication Co- Outcome
No. (Age, Gender) (mg/ until until onset medication
day) Onset
8. Kumar and Schizophrenia, Risperi- 6 mg 9 Thioridazine, None With retrial of
Malone (16 yrs, Female) done months Zopiclone, risperidone and
(2000) Trifluoperizine dose  reduction
to 2 mg,
TD shows
improvement
9. Dubbelman Schizophrenia Risperi- *** *** *** Fluoxetine ***
et al (Disorganized) done
(1998) with depression,
(28 yrs.)
10. Suzuki et al Schizophrenia, Risperi- 3-6mg 2 month None Biperidin 3mg Risperidone was
(2002) (40 yrs. Female) done was added stopped and
olanzapine
started; TD
disappears.
11. Suzuki et al Schizophrenia, Risperi- 9mg 3 weeks Amoxapine Biperidin Risperidone
(2002) (28 yrs, Female) done 6mg/day stopped. Queti-
apine replace-
ment done;
TD disappears.
12. Suzuki et al Schizophrenia, Risperi- 2mg 2 month Haloperidol, Biperidin Replacement
(2002) (24 yrs, Female) done Chlorpromazine,2-4 mg with Quetia-
pine; TD
disappears.
Note: ***=information not available
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cases by decreasing the dose of the drug, tardive dyskinesia
disappears (case number 8). These facts create problems
in understanding the mechanism of the induction of tardive
dyskinesia by atypical antipsychotics. Casey (2004) has also
highlighted that explaining this mechanism remains a
substantial challenge.
Four postulations have been proposed in explaining the
association of fewer drug induced movement disorders with
atypical antipsychotics as compared to conventional agents
(Casey, 2004). First postulation is that atypical antipsychotic
has greater activity in blocking serotonin-2A receptors than
dopamine-2 (D2) receptors. Secondly, atypical antipsychotics
block D2 receptors only long enough to cause an
antipsychotic action, but not as long as conventional agents.
Thirdly, in Tardive dyskinesia, the nigrostriatal dopamine
receptor system might develop increased sensitivity to
dopamine as a result of treatment with conventional agents,
but this may not occur with atypical antipsychotics. The
last one postulation is that there might be a genetic association
in its development and the dopamine D
3 allele.
The other critical issue in these reports is the fact that in
seven cases of risperidone induced and three cases of
olanzapine induced tardive dyskinesia there was exposure
to typical antipsychotics prior to initiation of risperidone or
olanzapine. As tardive dyskinesia is a longterm adverse
effect of antipsychotic drugs. Evolution of tardive dyskinesia
Table 3
OLANZAPINE AND TARDIVE DYSKINESIA
Sl. Author Diagnosis Drug Dose Interval Medication Co- Outcome
No. (Age, Gender) (mg/ until until onset medication
day) Onset
13. Dunayevich Schizophrenia Olanza- *** 7 Loxapine Divalproex Clozapine
and (40 yr. Female) pine months Reserpine 1250mg 200mg/day
Strakowski Haloperidol 50%
(1996) Trazonil improvement
Botulinum toxin
Vitamin E
14. Gunal et al Paranoid Olanza- *** 1 year None None ***
(1996) Schizophrenia pine
(21yrs. ,Male)
15. Herran and Schizophrenia Olanza- 10mg 2 Haloperidol Trihexyphenidyl TD
Barquero (30yrs.,Female) pine Max.= months 10mg/day 6 mg/day remained
(1999) 30mg unchanged
16. Herran and Schizophrenia Olanza- 10mg 7 Fluphenazine None With clozapine
Barquero (65yr.,Female) pine Max= months decanoate treatment after
1999) 20mg 25mg/month stopping
olanzapine
showed  no
improvement
17. Benazzi Huntington Olanza- *** *** *** *** ***
(2002) disease pine
18. Ananth and Paranoid Olanza- 20 mg 5 years None None Persisting on
Kenan Schizophrenia pine 20 mg
(1999) (25 yrs,Male)
19. Sidana et al Paranoid Olanza- 15 mg 7 None Tetrabenazine Olanzapine
(2004) Schizophrenia pine months added stopped,TD
(43yrs, Male) disappears
20. Koch et al *** Olanza- *** *** None Tiapride and ***
(2003) (71 yrs,Female) pine Tetrabenazine
21. Bella and Behavioural Olanza- 10 mg 4 month None None Vit.
Piccoli disorder pine E,lorazepam,
(2002) (62 yrs,female) Tiapride started
22. Snoddgrass Alcohol related Olanza- 5mg 1 month Risperidone None Olanzapine
et al (1999) disorder pine stopped,
(58 years,male) showed
improvement
Note: ***=information not available
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could simply be attributed to previous conventional
antipsychotics. But in eight reported cases this assumption
is negated as there was history of only monotherapy at
onset of illness with either risperidone (N=3, case no.3, 5,
10) or olanzapine (N=5, case no.14, 18 to 21). In these
three risperidone induced cases, all were females and
interval of onset of TD was in the range of 2 to 18 months
after initiation of risperidone. In contrast to these finding in
olanzapine induced cases, three patients were male and
two were females. Interval of onset of development of TD
in these patients was in the range of 4 months to 5 years.
In these reported cases it was clearly demonstrated that
there is a cause and effect relationship of risperidone or
olanzapine with tardive dyskinesia.
These published reports had some limitations which posed
difficulties in analysis of these cases. The use of
polypharmacy in some cases was adopted. No long term
drug free observation period or rechallenge with the
provoking drug was used in these reports. Precise
information was not available in few cases. Thus findings
cannot be generalized.
But we cannot ignore the significance of these reports and
these raise the level of concern in an important clinical
problem. The role of these drugs in induction of tardive
dyskinesia requires more clarification.
As the best treatment of tardive dyskinesia is prevention
only and these reported cases suggest the need for judicious
use of risperidone and olanzapine in clinical practice. Regular
monitoring for the development and early diagnosis of tardive
dyskinesia is needed. Careful assessment is warranted when
schizophrenic patient are given maintenance therapy with
these drugs. Their use in behavioural subjects in the absence
of psychosis should be avoided. Promise of atypical
antipsychotics being safer drug is being challenged and will
be clear in the next few years. There has been insufficient
duration of experience and adequate follow-up with
risperidone or olanzapine to test the hypothesis that they
have a low prevalence of tardive dyskinesia. More intensive
research and long term studies in the future are needed to
address the various issues raised by these case reports.
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